Cargando…
Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials
PURPOSE: A growing body of preclinical and observational research suggests that statins have potential as a therapeutic strategy in patients with cancer. This systematic review of randomised controlled trials (RCTs) in patients with solid tumours aimed to determine the efficacy of statin therapy on...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661422/ https://www.ncbi.nlm.nih.gov/pubmed/32719919 http://dx.doi.org/10.1007/s00228-020-02967-0 |
_version_ | 1783609205926658048 |
---|---|
author | Thomas, John P. Loke, Yoon K. Alexandre, Leo |
author_facet | Thomas, John P. Loke, Yoon K. Alexandre, Leo |
author_sort | Thomas, John P. |
collection | PubMed |
description | PURPOSE: A growing body of preclinical and observational research suggests that statins have potential as a therapeutic strategy in patients with cancer. This systematic review of randomised controlled trials (RCTs) in patients with solid tumours aimed to determine the efficacy of statin therapy on mortality outcomes, their safety profile and the risk of bias of included studies. METHODS: Full-text articles comparing statin therapy versus control in solid tumours and reporting mortality outcomes were identified from Medline and Embase from conception to February 2020. A systematic review with qualitative (primarily) and quantitative synthesis was conducted. This systematic review was prospectively registered (Prospero registration CRD42018116364). RESULTS: Eleven trials of 2165 patients were included. Primary tumour sites investigated included lung, colorectal, gastro-oesophageal, pancreatic and liver. Most trials recruited patients with advanced malignancy and used sub-maximal statin doses for relatively short durations. Aside from one trial which demonstrated benefit with allocation to pravastatin 40 mg in hepatocellular carcinoma, the remaining ten trials did not demonstrate efficacy with statins. The pooled hazard ratio for all-cause mortality with allocation to pravastatin in patients with hepatocellular carcinoma in two trials was 0.69 (95% confidence interval CI 0.30–1.61). Study estimates were imprecise. There were no clinically important differences in statin-related adverse events between groups. Overall, included trials were deemed low risk of bias. CONCLUSION: The trial evidence is not sufficiently robust to confirm or refute the efficacy and safety of statins in patients with solid malignant tumours. Study and patient characteristics may explain this uncertainty. The potential role of high-dose statins in adjuvant settings deserves further research. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-020-02967-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7661422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-76614222020-11-13 Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials Thomas, John P. Loke, Yoon K. Alexandre, Leo Eur J Clin Pharmacol Review PURPOSE: A growing body of preclinical and observational research suggests that statins have potential as a therapeutic strategy in patients with cancer. This systematic review of randomised controlled trials (RCTs) in patients with solid tumours aimed to determine the efficacy of statin therapy on mortality outcomes, their safety profile and the risk of bias of included studies. METHODS: Full-text articles comparing statin therapy versus control in solid tumours and reporting mortality outcomes were identified from Medline and Embase from conception to February 2020. A systematic review with qualitative (primarily) and quantitative synthesis was conducted. This systematic review was prospectively registered (Prospero registration CRD42018116364). RESULTS: Eleven trials of 2165 patients were included. Primary tumour sites investigated included lung, colorectal, gastro-oesophageal, pancreatic and liver. Most trials recruited patients with advanced malignancy and used sub-maximal statin doses for relatively short durations. Aside from one trial which demonstrated benefit with allocation to pravastatin 40 mg in hepatocellular carcinoma, the remaining ten trials did not demonstrate efficacy with statins. The pooled hazard ratio for all-cause mortality with allocation to pravastatin in patients with hepatocellular carcinoma in two trials was 0.69 (95% confidence interval CI 0.30–1.61). Study estimates were imprecise. There were no clinically important differences in statin-related adverse events between groups. Overall, included trials were deemed low risk of bias. CONCLUSION: The trial evidence is not sufficiently robust to confirm or refute the efficacy and safety of statins in patients with solid malignant tumours. Study and patient characteristics may explain this uncertainty. The potential role of high-dose statins in adjuvant settings deserves further research. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-020-02967-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-07-28 2020 /pmc/articles/PMC7661422/ /pubmed/32719919 http://dx.doi.org/10.1007/s00228-020-02967-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Thomas, John P. Loke, Yoon K. Alexandre, Leo Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials |
title | Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials |
title_full | Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials |
title_fullStr | Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials |
title_full_unstemmed | Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials |
title_short | Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials |
title_sort | efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661422/ https://www.ncbi.nlm.nih.gov/pubmed/32719919 http://dx.doi.org/10.1007/s00228-020-02967-0 |
work_keys_str_mv | AT thomasjohnp efficacyandsafetyprofileofstatinsinpatientswithcancerasystematicreviewofrandomisedcontrolledtrials AT lokeyoonk efficacyandsafetyprofileofstatinsinpatientswithcancerasystematicreviewofrandomisedcontrolledtrials AT alexandreleo efficacyandsafetyprofileofstatinsinpatientswithcancerasystematicreviewofrandomisedcontrolledtrials |